This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?
by Zacks Equity Research
AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.
Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.
McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.
What's in Store for Express Scripts (ESRX) in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.
GNC Holdings (GNC) Q2 Earnings: Disappointment in the Cards?
by Zacks Equity Research
We do not expect GNC Holdings (GNC) to beat estimates in Q2 earnings on account of a tough competitive landscape and currency headwinds.
Top Analyst Reports for Procter & Gamble, Verizon & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Verizon (VZ) and Citigroup (C).
MedTech Thriving on Consolidation & Expansion: Stocks to Buy
by Zacks Equity Research
The industry has some powerful long-term tailwinds of the medical device industry like mergers & acquisitions (M&A), emerging market expansion, positive demographic trends and new product innovation.
Why Is Becton, Dickinson (BDX) Up 3% Since the Last Earnings Report?
by Zacks Equity Research
Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for May 4, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), JPMorgan (JPM) and Union Pacific (UNP).
Becton, Dickinson (BDX) Beats On Earnings & Revenues In Q2
by Zacks Equity Research
Becton, Dickinson's adjusted earnings of $2.30 per share beat the Zacks Consensus Estimate by 7 cents and increased 5.5% from $2.18 posted in the year-ago quarter.